HUP0301991A2 - IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére - Google Patents

IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére

Info

Publication number
HUP0301991A2
HUP0301991A2 HU0301991A HUP0301991A HUP0301991A2 HU P0301991 A2 HUP0301991 A2 HU P0301991A2 HU 0301991 A HU0301991 A HU 0301991A HU P0301991 A HUP0301991 A HU P0301991A HU P0301991 A2 HUP0301991 A2 HU P0301991A2
Authority
HU
Hungary
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
subject
Prior art date
Application number
HU0301991A
Other languages
English (en)
Inventor
Yolande Chvatchko
Ziad Mallat
Alain Tedgui
Original Assignee
Applied Research Systems Ars Holding N.V.
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Applied Research Systems Ars Holding N.V.
Publication of HUP0301991A2 publication Critical patent/HUP0301991A2/hu
Publication of HUP0301991A3 publication Critical patent/HUP0301991A3/hu
Publication of HU229375B1 publication Critical patent/HU229375B1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány szerinti megoldás a vaszkuláris betegségek tárgykörébetartozik. A találmány tárgya közelebbről IL-18-inhibitorok alkalmazásaatheroszklerózis kezelésére és/vagy megelőzésére. Ó
HU0301991A 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis HU229375B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (3)

Publication Number Publication Date
HUP0301991A2 true HUP0301991A2 (hu) 2003-09-29
HUP0301991A3 HUP0301991A3 (en) 2006-11-28
HU229375B1 HU229375B1 (en) 2013-11-28

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301991A HU229375B1 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Country Status (33)

Country Link
US (1) US20040076628A1 (hu)
EP (1) EP1278540B1 (hu)
JP (1) JP5122053B2 (hu)
KR (2) KR100798545B1 (hu)
CN (2) CN1841066B (hu)
AR (1) AR035640A1 (hu)
AT (1) ATE395075T1 (hu)
AU (2) AU6739001A (hu)
BG (1) BG65881B1 (hu)
BR (1) BRPI0110506B8 (hu)
CA (1) CA2407895C (hu)
CY (1) CY1110385T1 (hu)
CZ (1) CZ300792B6 (hu)
DE (1) DE60134009D1 (hu)
DK (1) DK1278540T3 (hu)
EA (2) EA005410B1 (hu)
EE (1) EE05056B1 (hu)
ES (1) ES2305082T3 (hu)
HK (2) HK1055681A1 (hu)
HR (1) HRP20020828A2 (hu)
HU (1) HU229375B1 (hu)
IL (2) IL152567A0 (hu)
ME (1) ME00554B (hu)
MX (1) MXPA02010895A (hu)
NO (1) NO329821B1 (hu)
PL (1) PL209371B1 (hu)
PT (1) PT1278540E (hu)
RS (1) RS50926B (hu)
SI (1) SI1278540T1 (hu)
SK (1) SK287761B6 (hu)
UA (2) UA87658C2 (hu)
WO (1) WO2001085201A2 (hu)
ZA (1) ZA200208228B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CA2435466C (en) * 2001-01-29 2012-04-03 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of heart disease
PL216228B1 (pl) * 2001-05-25 2014-03-31 Ares Trading Sa Zastosowanie białka wiążącego IL-18
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
UA80275C2 (en) 2002-03-22 2007-09-10 Applied Research Systems Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases (variants)
CA2516157C (en) * 2003-03-11 2012-09-18 Applied Research Systems Ars Holding N.V. Expression vectors comprising the mcmv ie2 promoter
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Il−18結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AU2005232436C1 (en) * 2004-04-15 2010-08-26 Athera Biotechnologies Ab Annexin V for preventing atherothrombosis and plaque rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术(上海)有限公司 白介素-22的医药用途
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
ATE529433T1 (de) 2005-06-10 2011-11-15 Ares Trading Sa Verfahren zur reinigung eines il-18-bindenden proteins
TW201215405A (en) 2010-08-25 2012-04-16 Hoffmann La Roche Antibodies against IL-18R1 and uses thereof
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
PL3041864T3 (pl) 2013-09-05 2021-12-20 Ab2 Bio Sa Białko wiążące il-18 (il-18bp) w chorobach zapalnych
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Il-18拮抗劑用於治療和/或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18

Also Published As

Publication number Publication date
BG107218A (bg) 2003-06-30
WO2001085201A3 (en) 2002-05-10
HRP20020828A2 (en) 2004-12-31
NO20025307L (no) 2002-12-18
WO2001085201A2 (en) 2001-11-15
JP5122053B2 (ja) 2013-01-16
SK15562002A3 (sk) 2003-05-02
IL152567A0 (en) 2003-05-29
EA005410B1 (ru) 2005-02-24
EE200200620A (et) 2004-06-15
MXPA02010895A (es) 2003-03-27
EA200401183A1 (ru) 2004-12-30
CN1841066A (zh) 2006-10-04
AR035640A1 (es) 2004-06-23
ZA200208228B (en) 2005-07-27
PL209371B1 (pl) 2011-08-31
CN1841066B (zh) 2012-08-29
UA78492C2 (en) 2007-04-10
UA87658C2 (uk) 2009-08-10
SI1278540T1 (sl) 2008-10-31
HU229375B1 (en) 2013-11-28
CA2407895C (en) 2012-12-18
AU6739001A (en) 2001-11-20
CZ300792B6 (cs) 2009-08-12
BR0110506A (pt) 2003-04-01
DK1278540T3 (da) 2008-07-21
PT1278540E (pt) 2008-07-03
EE05056B1 (et) 2008-08-15
IL152567A (en) 2010-12-30
BRPI0110506B1 (pt) 2015-05-19
CZ20023644A3 (cs) 2003-03-12
CN1434722A (zh) 2003-08-06
SK287761B6 (en) 2011-09-05
EP1278540B1 (en) 2008-05-14
HK1055681A1 (en) 2004-01-21
ES2305082T3 (es) 2008-11-01
ATE395075T1 (de) 2008-05-15
RS50926B (sr) 2010-08-31
NO20025307D0 (no) 2002-11-05
YU82602A (sh) 2006-01-16
NO329821B1 (no) 2010-12-27
HUP0301991A3 (en) 2006-11-28
KR100798545B1 (ko) 2008-01-28
BG65881B1 (bg) 2010-04-30
CY1110385T1 (el) 2015-04-29
EA200201175A1 (ru) 2003-04-24
DE60134009D1 (de) 2008-06-26
EA007014B1 (ru) 2006-06-30
CN1250286C (zh) 2006-04-12
KR20030016254A (ko) 2003-02-26
MEP64008A (en) 2011-12-20
KR20070073989A (ko) 2007-07-10
US20040076628A1 (en) 2004-04-22
CA2407895A1 (en) 2001-11-15
PL365697A1 (en) 2005-01-10
EP1278540A2 (en) 2003-01-29
AU2001267390B2 (en) 2005-09-22
BRPI0110506B8 (pt) 2021-05-25
HK1094909A1 (en) 2007-04-13
ME00554B (me) 2012-03-20
JP2003532685A (ja) 2003-11-05

Similar Documents

Publication Publication Date Title
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
ME00548B (me) Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti
HUP0301281A2 (hu) Új gyógyászati készítmény
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
HUP0003852A2 (hu) Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
BRPI0416680A (pt) inibidores da forma mutante de kit
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
ME00489B (me) NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL
ME00550B (me) Korišćenje il-18 inhibitora za lećenje ili prevenciju povreda cns
TNSN05154A1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
HUP0401323A2 (hu) IL-18 inhibitorok alkalmazása túlérzékenységi rendellenességek esetén
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
DE60221692D1 (de) Kombination eines atp-competitiven inhibitors der bcr/abl kinase und eines tyrphostin analogen
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
WO2002055064A3 (en) Mucopolysaccharidosis therapies
UA64813C2 (uk) Інтраназальний антисептик

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERCK SERONO SA, CH

Free format text: FORMER OWNER(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., NL

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Free format text: FORMER OWNER(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., NL